27 July 2012 - Horizon Pharma Inc (NASDAQ: HZNP), a biopharmaceutical company that is developing and commercialising medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, announced today that its RAYOS(r) (prednisone) delayed-release tablets have received approval...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up